• Modern aspects of external anti’inflammatory therapy of atopic dermatitis in children 

Modern aspects of external anti’inflammatory therapy of atopic dermatitis in children 

SOVREMENNAYA PEDIATRIYA.2016.2(74):92-99; doi 10.15574/SP.2016.74.92 

Modern aspects of external anti'inflammatory therapy of atopic dermatitis in children 

Okhotnikova O. M., Yakovleva N. Y., Chernysh Y. R.

National Medical Academy of postgraduate education named after P.L.Shupyk, Kyiv, Ukraine 

Objective: to evaluate the effectiveness and safety of combined use of creams Prednicarbum and synthetic tannin (phenol-methanal-of urea-polycondensate) in the treatment of exacerbation of atopic dermatitis in children. 

Material and methods: 50 children, 1 to 12 years, with atopic dermatitis with the exacerbation of the skin process different degrees of severity.

Results: In children with mild localized form of atopic dermatitis after the monotherapy whith cream synthetic tannin, noted a marked clinical improvement up to 7 days of treatment. The noted expressive positive dynamics of the skin process and reduction of objective symptoms during the first days after of combination treatment with Prednicarbatet cream and synthetic tannin, also after combination therapy Prednicarbate and moisturizing cream in mode of step therapy.

Conclusions: The combined application of Prednicarbate cream and phenol-methanal-of urea-polycondensate increases the effectiveness of anti-inflammatory treatment of atopic dermatitis, which can reduce the duration of use of topical corticosteroids and reduce the risk of adverse reactions in children with moderate and severe course skin process.

Key words: atopic dermatitis, topical corticosteroids Prednicarbate, topical nonsteroidal antiinflammatory drugs (synthetic tannin — phenol-methanal-of urea-polycondensate), children.


1. Aryaev NL. 2005. The modern treatment strategy of atopic dermatitis in children. Sovr pedyatryya. 3(8): 65–68.

2. Holovchenko DYa, Puryshkyna OD, Solohub LV. 2011. The use of non-halogenated glucocorticoid drug "Prednitop" in the topical treatment of diffused dermatoses. Dermatolohiya ta venerolohiya. 2: 127-128.

3. Holovchenko DYa, Puryshkyna OD, Solohub LV. 2011. The use of a new drug synthetic tannins "Delaskin" in the treatment of acute inflammatory lesions of skin. Dermatolohiya ta venerolohiya. 2: 127.

4. Klymenko VA, Kozhemyaka AY, Adaryukova LM at al. 2012. Delaskin – new possibilities treatment of atopic dermatitis in children in Ukraine. Zdorov'e rebenka. 5(40): 75-79.

5. Yvanov O. Skin and venereal diseases. http://readr.ru/oleg-ivanov-koghnie-i-venericheskie-bolezni.html.

6. Lasytsya OL, Lasytsya TS, Nedel's'ka SM. 2004. Allergollogy of childhood. K, Knyha plyus: 367.

7. Okhotnikova OM, Yakovleva NYu. 2013. Atopic dermatitis in children. Section "Allergic diseases in children". Pediatriya. Natsional'nyy pidruchnyk dlya pislyadyplomnoyi osvity. Za red VV Berezhnoho. Kyyiv. 1; 8: 473-577.

8. Okhotnikova OM. 2011. Atopic dermatitis: modern consideration of pediatric and allergologist. Likars'ka sprava. 3-4: 29-41.

9. Svyrshchevskaya EV, Matushevskaya EV. 2010. Comparative analysis of the efficacy and safety of fluorinated and chlorinated topical corticosteroids. Sovremennыe osnovы dermatovenerolohyy, ymmunolohyy y kosmetolohyy. 3: 75-78..

10. Bottger G. 2000. Topisches Kortikoid in der taglichen Behandlung von Kindern mit Neurodermitis. Hautnah dermatologie. 3: 27—37.

11. Dermapharm AG — Clinical study reports 01-02/PC-C, GKM Gesellschaft fur Therapieforschung mbH Munchen, 2003.

12. Dermapharm AG — Clinical study reports 01-03/PC-S, GKM Gesellschaft fur Therapieforschung mbH Munchen, 2003.

13. Dermapharm AG — Clinical study reports 01-01/PC-FS, GKM Gesellschaft fur Therapieforschung mbH Munchen, 2003.

14. Folster-Holst R, Latussek E. 2007. Synthetic Tannins in Dermatology — A Therapeutic Option in a Variety of Pediatric Dermatoses. Pediatric Dermatology. 3; 24: 296—301.

15. Fougera E. et al. 2006, Jan. PREDNICARBATE — prednicarbate ointment. http: //PatientsVille.com,

16. Ellis C, Luger T, Abeck D et al. 2003, May. International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies. Brit J Dermatol. 148; Suppl 63: 3—10.

17. Glukokortikoide bleiben weiterhin unverzichtbar. Dermatologie. 2002. 2: 46—54.

18. Hanifіn JM, Rajka G. 1980. Diagnostic features of atopic dermatitis. Acta Dermatol Venereol. 92: 44.

19. Novak N, Bieber T, Leung DYM. 2003. Immune mechanisms leading to atopic dermatitis. J Allergy Clin Immunol. 112; 6: 128—139.

20. Korting HC, Vieluf D, Kerscher M. 1992. 0,25% prednicarbat cream and the corresponding vehicle induce less skin atrophy than 0,1% betamethason-17-valerate cream and 0,5% clobetasol-17-propionate cream. Eur J Clin Pharmacol. 42: 159.

21. Korting HC et al. 2002. Skin Pharmacol Appl. Skin Physiol. 15: 51—54.

22. Kunzer W, Nikulla G. 1987. Behandlung der Varizellen mit einem synthetischen Gerbstoff. Kinderarzt. 18: 1592—1595.

23. Spergel JM, Paller ASS. 2003. Atopic dermatitis and the atopic march. J Allergy Clin Immunol. 112; 6 (suppl): 118—127.